Trial Profile
A Phase II Trial of Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms ILIAD
- 12 Oct 2021 Status changed from discontinued to completed.
- 08 Dec 2020 Primary endpoint (Overall response rate for the Germinal Center B-cell (GCB) subtype of diffuse large B-cell lymphoma.) has not been met, according to results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2020 Status changed to discontinued, according to results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology